CN1824320A - 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 - Google Patents
含有钙通道阻滞剂和b族维生素的药物组合物及其用途 Download PDFInfo
- Publication number
- CN1824320A CN1824320A CNA200610000693XA CN200610000693A CN1824320A CN 1824320 A CN1824320 A CN 1824320A CN A200610000693X A CNA200610000693X A CN A200610000693XA CN 200610000693 A CN200610000693 A CN 200610000693A CN 1824320 A CN1824320 A CN 1824320A
- Authority
- CN
- China
- Prior art keywords
- group
- folic acid
- amlodipine
- vitamin
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 14
- 102000040350 B family Human genes 0.000 title abstract 2
- 108091072128 B family Proteins 0.000 title abstract 2
- 239000011782 vitamin Substances 0.000 title abstract 2
- 229940088594 vitamin Drugs 0.000 title abstract 2
- 229930003231 vitamin Natural products 0.000 title abstract 2
- 235000013343 vitamin Nutrition 0.000 title abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title description 2
- 239000011575 calcium Substances 0.000 title description 2
- 229910052791 calcium Inorganic materials 0.000 title description 2
- 150000003722 vitamin derivatives Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 20
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 11
- 208000006011 Stroke Diseases 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000002207 metabolite Substances 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 9
- 206010019280 Heart failures Diseases 0.000 claims abstract description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 3
- 201000006370 kidney failure Diseases 0.000 claims abstract description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 286
- 235000019152 folic acid Nutrition 0.000 claims description 146
- 239000011724 folic acid Substances 0.000 claims description 146
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 144
- 229960000304 folic acid Drugs 0.000 claims description 144
- 206010020772 Hypertension Diseases 0.000 claims description 141
- 229960000528 amlodipine Drugs 0.000 claims description 106
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 57
- 239000000480 calcium channel blocker Substances 0.000 claims description 54
- 230000036772 blood pressure Effects 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 45
- 229960001597 nifedipine Drugs 0.000 claims description 36
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 36
- 239000003826 tablet Substances 0.000 claims description 35
- 235000019156 vitamin B Nutrition 0.000 claims description 31
- 239000011720 vitamin B Substances 0.000 claims description 31
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 30
- 229930003270 Vitamin B Natural products 0.000 claims description 30
- 229960005425 nitrendipine Drugs 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 29
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 27
- 125000003929 folic acid group Chemical group 0.000 claims description 27
- 229960003580 felodipine Drugs 0.000 claims description 26
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 19
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 16
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 claims description 15
- 229960004005 amlodipine besylate Drugs 0.000 claims description 15
- 229950008554 levamlodipine Drugs 0.000 claims description 15
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 15
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 14
- 229960004166 diltiazem Drugs 0.000 claims description 14
- 235000019158 vitamin B6 Nutrition 0.000 claims description 14
- 239000011726 vitamin B6 Substances 0.000 claims description 14
- 229940011671 vitamin b6 Drugs 0.000 claims description 14
- 229930003779 Vitamin B12 Natural products 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 13
- 235000019163 vitamin B12 Nutrition 0.000 claims description 13
- 239000011715 vitamin B12 Substances 0.000 claims description 13
- 208000029078 coronary artery disease Diseases 0.000 claims description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 11
- 239000011976 maleic acid Substances 0.000 claims description 11
- 230000008816 organ damage Effects 0.000 claims description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 10
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 10
- 229960001783 nicardipine Drugs 0.000 claims description 10
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 7
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 7
- 229960004427 isradipine Drugs 0.000 claims description 7
- 229960004340 lacidipine Drugs 0.000 claims description 7
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims description 7
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000227 nisoldipine Drugs 0.000 claims description 7
- 229960001722 verapamil Drugs 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 229940098895 maleic acid Drugs 0.000 claims description 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 4
- 230000001934 delay Effects 0.000 claims description 4
- 201000009925 nephrosclerosis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 210000000709 aorta Anatomy 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000002224 dissection Methods 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000000505 pernicious effect Effects 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract description 3
- 208000032843 Hemorrhage Diseases 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 137
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 97
- 230000001631 hypertensive effect Effects 0.000 description 67
- 210000003734 kidney Anatomy 0.000 description 41
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 230000006870 function Effects 0.000 description 27
- 210000002700 urine Anatomy 0.000 description 26
- 230000001077 hypotensive effect Effects 0.000 description 25
- 210000000056 organ Anatomy 0.000 description 24
- 229920002472 Starch Polymers 0.000 description 23
- 235000019698 starch Nutrition 0.000 description 23
- 239000008107 starch Substances 0.000 description 23
- 210000002216 heart Anatomy 0.000 description 21
- 210000001367 artery Anatomy 0.000 description 20
- 238000000576 coating method Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 17
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 16
- 235000019359 magnesium stearate Nutrition 0.000 description 16
- 206010020880 Hypertrophy Diseases 0.000 description 15
- 208000034189 Sclerosis Diseases 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 102000002045 Endothelin Human genes 0.000 description 13
- 108050009340 Endothelin Proteins 0.000 description 13
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 230000002269 spontaneous effect Effects 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 description 12
- 239000008108 microcrystalline cellulose Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 231100000915 pathological change Toxicity 0.000 description 11
- 230000036285 pathological change Effects 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 206010003694 Atrophy Diseases 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 230000037444 atrophy Effects 0.000 description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 9
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 238000013270 controlled release Methods 0.000 description 9
- 230000003907 kidney function Effects 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000002784 sclerotic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000000004 hemodynamic effect Effects 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 206010038464 renal hypertension Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 208000004670 arteriolosclerosis Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 150000002224 folic acids Chemical class 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000002254 renal artery Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- -1 Polyoxyethylene Polymers 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 208000034777 Vitreous degeneration Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 201000011288 vitreous syneresis Diseases 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000036316 preload Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 206010052337 Diastolic dysfunction Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 208000031816 Pathologic Dilatation Diseases 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000008508 epithelial proliferation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 229940019142 folic acid 5 mg Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OAJLVMGLJZXSGX-NDSREFPTSA-L (2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12 Chemical compound [Co+3].O[C@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-NDSREFPTSA-L 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- HFTAHCASHDQCSP-UHFFFAOYSA-N 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol phosphoric acid Chemical compound OP(O)(O)=O.CC1=NC=C(CO)C(CN)=C1O HFTAHCASHDQCSP-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005276 aerator Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940066469 amlodipine 5 mg Drugs 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MCTRZKAKODSRLQ-UHFFFAOYSA-N dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 MCTRZKAKODSRLQ-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940083626 folic acid 0.4 mg Drugs 0.000 description 1
- 229940083565 folic acid 0.8 mg Drugs 0.000 description 1
- 229940083563 folic acid 1 mg Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 238000011616 hypertension animal model Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940089133 vitamin b6 5 mg Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 动物数(只) | 降压幅度(mmHg) | 24h尿α1微球蛋白(ug) |
正常组模型组叶酸维生素B6维生素B12氨氯地平氨氯地平氨氯地平+叶酸氨氯地平+VitB6氨氯地平+VitB12 | 等容量等容量0.0410.10.30.50.3+0.040.3+10.3+0.1 | 12181919182020201920 | -2.1±4.0-10.5±6.3-6.9±8.6-12.0±5.1-7.3±5.215.0±5.9**20.4±10.8**23.9±6.9**▲▲17.9±4.6**20.9±3.6**▲ | 29.8±6.9102.4±31.085.5±19.696.6±27.495.3±27.578.7±20.4*68.2±26.9**54.9±20.4**▲▲60.4±17.6**▲64.8±15.8**▲ |
组别 | 剂量(mg/kg) | 动物数(只) | 降压幅度(mmHg) | 24h尿α1微球蛋白(ug) |
正常组模型组叶酸维生素B6维生素B12尼群地平尼群地平尼群地平+叶酸尼群地平+VitB6尼群地平+VitB12 | 等容量等容量0.0410.12.03.02.0+0.042.0+12.0+0.1 | 12192020181920201920 | -1.8±5.0-8.3±3.8-5.2±3.4-7.0±4.9-10.3±6.635.0±8.4**44.4±9.5**48.9±7.0**▲▲42.9±7.6**▲43.0±5.2**▲ | 14.3±6.080.9±20.365.5±13.076.9±17.373.0±14.058.7±10.6*48.2±14.6**44.9±13.6**▲▲46.4±12.2**▲▲50.8±7.6**▲ |
组别 | 剂量(mg/kg) | 动物数(只) | 降压幅度(mmHg) |
正常组模型组叶酸硝苯地平硝苯地平硝苯地平+叶酸 | 等容量等容量0.081.01.51.0+0.08 | 101515151515 | 1.8±3.21.5±3.73.5±2.825.0±7.8**33.8±6.2**32.2±5.0**▲ |
组别 | 剂量(mg/kg) | LVEDP(mmHg) | T(ms) | 左心重/体重(mg/g) |
正常组模型组叶酸马米酸左旋氨氯地平马来酸左旋氨氯地平马米酸左旋氨氯地平+叶酸 | --0.080.510.5+0.08 | 2.0±1.822.9±4.918.9±4.810.4±3.8**7.2±3.4**6.8±3.4**▲ | 4.8±0.919.8±4.017.1±3.613.0±4.6**8.8±3.5**9.5±3.7**▲ | 1.90±0.242.99±0.292.68±0.342.05±0.37**2.07±0.39**2.01±0.27** |
组别 | 剂量(mg/kg) | 数量(n) | NO(mmol/L) | ET(pg/L) |
正常组高血压组氨氯地平氨氯地平+叶酸叶酸 | --0.50.5+0.040.5+0.080.5+0.160.5+0.50.08 | 1210121111111212 | 115.4±25.851.1±17.2**64.5±13.2▲72.9±21.8▲85.0±30.3▲▲★81.5±21.3▲▲★84.9±15.4▲▲★69.2±21.1▲ | 113.8±21.9167.3±31.2**137.6±19.5▲132.4±14.1▲▲124.8±17.1▲▲★130.3±20.4▲▲122.4±17.5▲▲★149.5±22.2 |
组别 | 剂量(mg/kg) | 动物数 | α1-微球蛋白浓度(μg/ml) | 24h尿量(ml) | 24hα1-微球蛋白(μg) |
正常组高血压组氨氯地平氨+叶酸叶酸 | --0.50.5+0.040.5+0.080.5+0.160.5+0.50.08 | 1210121111111212 | 0.42±0.271.87±0.79**1.16±0.46▲▲0.83±0.23▲▲★0.81±0.45▲▲★0.94±0.54▲▲0.88±0.77▲▲1.49±0.71 | 20.6±7.523.8±6.423.3±4.323.7±5.121.7±7.920.9±8.822.3±6.323.8±9.0 | 7.4±3.742.0±14.3**26.0±9.0▲▲19.3±5.9▲▲★15.1±6.0▲▲★★16.2±5.6▲▲★★18.1±6.7▲▲★32.3±9.8▲ |
组别 | 剂量(mg/kg) | 动物数 | 尿蛋白浓度(μg/ml) | 24h尿量(ml) | 尿蛋白(mg) |
正常组高血压组氨氯地平氨+叶酸叶酸 | --0.50.5+0.040.5+0.080.5+0.160.5+0.50.08 | 1210121111111212 | 396.6±145.41587.5±358.1**1226.9±294.3▲▲1188.2±299.3▲▲921.3±212.6▲▲★★938.0±354.7▲▲1002.9±274.0▲▲1593.9±398.3 | 17.6±4.219.0±3.018.8±4.217.3±5.016.4±4.317.8±4.219.6±3.818.2±4.6 | 7.1±3.430.2±7.9**22.6±6.3▲19.9±5.4▲▲15.1±5.0▲▲★★16.3±6.1▲▲★★17.6±5.2▲▲28.4±9.0 |
组别 | 剂量(mg/kg) | 动物数 | Scr(μmol/L) | 24h尿肌酐(mmol) | Ccr(ml/min) | BUN(mmol/L) |
正常组高血压组氨氯地平氨+叶酸叶酸 | --0.50.5+0.040.5+0.080.5+0.160.5+0.50.08 | 1210111111111212 | 92.8±10.799.3±24.689.1±10.191.0±27.186.0±17.793.4±13.498.1±9.494.4±19.4 | 49.0±16.615.4±4.528.9±7.034.1±9.537.3±12.339.9±4.520.6±7.322.7±9.7 | 0.364±0.1100.121±0.033**0.226±0.049▲▲0.270±0.068▲▲0.297±0.071▲▲★0.301±0.052▲▲★★0.315±0.080▲▲★0.166±0.052 | 7.28±0.797.74±0.467.21±0.307.65±0.447.10±0.217.01±0.337.30±0.917.36±0.46 |
组别 | LVSP(mmHg) | LVEDP(mmHg) | +dp/dtmax(×103,mmHg/s) | -dp/dtmax(×103,mmHg/s) |
正常组高血压组0.5+0.040.5+0.080.5+0.160.5+0.5氨0.5叶酸0.08 | 129.6±12.6183.2±22.4**144.3±15.5▲▲133.8±8.9▲▲★136.7±15.8▲▲★138.9±16.4▲▲148.7±9.5▲▲176.4±16.0 | -0.92±4.139.6±22.2**16.3±4.8▲▲★15.8±4.7▲▲★13.1±5.0▲▲★★11.6±10.7▲▲★21.7±4.8▲▲32.4±24.2 | 12.4±3.06.3±1.6**9.6±2.6▲▲11.1±2.8▲▲★10.5±2.0▲▲★11.9±2.1▲★8.5±1.7▲▲7.1±2.0 | 15.1±4.34.9±1.1**7.6±1.1▲▲★7.3±1.3▲▲7.2±1.9▲▲6.8±1.3▲▲6.4±1.2▲▲5.1±1.6 |
实验分组 | 动物数 | 病变组织 | 各组病理程度及动物数 | |||
病变显著 | 病变轻度 | 病变不明显 | ||||
正常组 | 12 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 100011 | 100012 | 10121212109 |
高血压组 | 10 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 877865 | 223243 | 010002 |
氨氯地平(0.5mg/kg) | 12 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 633533 | 447553 | 252246 |
氨氯地平+叶酸 | 11 | 心 | 心肌细胞肥大 | 2 | 8 | 1 |
组(0.5+0.04mg/kg) | 肾脾脑 | 心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 14521 | 55554 | 52146 | |
氨氯地平+叶酸组(0.5+0.08mg/kg) | 11 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 234322 | 543535 | 444364 |
氨氯地平+叶酸组(0.5+0.16mg/kg) | 11 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 113331 | 545446 | 563444 |
氨氯地平+叶酸组(0.5+0.5mg/kg) | 12 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 323442 | 545344 | 464546 |
叶酸组(0.08mg/kg) | 12 | 心肾脾脑 | 心肌细胞肥大心冠状动脉硬化肾小球萎缩或肥大肾细小动脉硬化间质纤维化中央动脉硬化小动脉硬化微血管增生 | 758665 | 362454 | 212213 |
组别 | 剂量(mg/kg) | 动物数 | 观察样本数 | 病变显著数 | 病变轻度数 | 病变不明显数 |
正常组高血压氨氯地平氨+叶酸叶酸 | --0.50.5+0.040.5+0.080.5+0.160.5+0.50.08 | 1210121111111212 | 7260726666667272 | 341231516121837 | 416283225282524 | 653211925262911 |
组别 | 剂量(mg/kg) | 数量(n) | NO(mmol/L) | ET(pg/L) |
正常组模型组氨氯地平+叶酸硝苯地平+叶酸尼群地平+叶酸非洛地平+叶酸地尔硫卓+叶酸 | --0.5+0.083+0.083+0.081+0.086+0.08 | 16131515131412 | 138.8±38.257.7±18.4**105.4±20.3▲▲74.5±13.2▲★82.9±21.8▲★86.0±19.7▲▲68.8±14.1▲★★ | 234.6±42.7366.8±65.5**216.5±57.4▲▲288.2±76.6▲★253.3±64.5▲▲234.8±47.1▲▲309.5±62.9★★ |
组别 | 剂量(/kg) | N | SOD(NkU/L) | MDA(umol/L) | 血小板聚集率(%) | |
最大聚集率 | 平均聚集率 | |||||
正常组模型组氨氯地平+叶酸硝苯地平+叶酸尼群地平+叶酸非洛地平+叶酸地尔硫卓+叶酸 | --0.5+0.083+0.083+0.081+0.086+0.08 | 16131515131412 | 201.3±46.4113.4±30.5**174.6±34.3▲▲138.8±26.8▲★154.3±31.2▲▲150.2±19.7▲▲★135.8±35.6★ | 0.46±0.102.56±0.52**1.25±0.42▲▲1.64±0.41▲▲★1.72±0.53▲▲★1.62±0.48▲▲★1.85±0.69▲★ | 13.2±3.135.3±5.3**24.5±4.9▲▲33.2±6.7★★30.5±5.8▲▲★28.4±8.4▲▲30.6±5.6★★ | 6.2±3.127.3±4.6**16.5±5.6▲▲22.4±6.6★★23.9±6.6★★18.3±5.5▲▲22.1±7.9 |
组别 | 剂量(mg/kg) | 动物数 | 尿蛋白(mg) | Ccr(ml/min) | 24hα1-微球蛋白(μg) |
正常组模型组氨氯地平+叶酸硝苯地平+叶酸尼群地平+叶酸非洛地平+叶酸地尔硫卓+叶酸 | --0.5+0.083+0.083+0.081+0.086+0.08 | 16131515131412 | 14.3±6.8106.8±37.4**49.6±10.7▲▲82.8±20.2▲★★69.9±16.9▲▲★★65.9±12.6▲▲★68.6±21.4▲▲★ | 0.454±0.1130.218±0.045**0.412±0.033▲▲0.283±0.056▲▲★0.338±0.077▲▲★0.347±0.110▲▲0.316±0.064▲▲★ | 20.8±10.4103.6±41.4**47.3±20.1▲▲70.3±24.9▲★69.3±15.4▲▲★65.1±18.8▲▲★80.5±24.5★★ |
组别 | LVSP(mmHg) | LVEDP(mmHg) | +dp/dtmax(×103,mmHg/s) | -dp/dtmax(×103,mmHg/s) |
正常组模型组氨氯地平+叶酸硝苯地平+叶酸尼群地平+叶酸非洛地平+叶酸地尔硫卓+叶酸 | 133.4±21.5213.3±26.4**140.6±18.7▲▲164.6±17.9▲▲★★156.7±15.8▲▲★158.9±26.4▲▲168.7±30.6▲▲★★ | -3.23±6.754.8±21.0**22.7±6.8▲▲30.4±7.5▲▲★★33.1±10.0▲▲★★30.6±10.7▲▲★41.7±4.8★★ | 14.8±3.95.4±2.9**12.5±4.8▲▲7.5±2.4▲★8.8±3.3▲▲★10.9±3.6▲▲6.8±2.7★★ | 16.1±2.96.6±2.112.2±3.2▲▲8.7±2.4▲▲★★8.2±2.6▲▲★★9.0±2.3▲▲★★5.4±3.2★★ |
组别 | 剂量(mg/kg) | 动物数 | 观察样本数 | 病变显著数 | 病变轻度数 | 病变不明显数 |
正常组模型组氨氯地平+叶酸硝苯地平+叶酸尼群地平+叶酸非洛地平+叶酸地尔硫卓+叶酸 | --0.5+0.083+0.083+0.081+0.086+0.08 | 16131515131412 | 96789090788472 | 3602748403643 | 6133030223320 | 875331216159 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610000693XA CN100551442C (zh) | 2005-01-13 | 2006-01-12 | 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510006959 | 2005-01-13 | ||
CN200510006959.7 | 2005-01-13 | ||
CNB200610000693XA CN100551442C (zh) | 2005-01-13 | 2006-01-12 | 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1824320A true CN1824320A (zh) | 2006-08-30 |
CN100551442C CN100551442C (zh) | 2009-10-21 |
Family
ID=36935262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610000693XA Active CN100551442C (zh) | 2005-01-13 | 2006-01-12 | 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100551442C (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143662A1 (zh) * | 2008-05-30 | 2009-12-03 | 北京奥萨医药研究中心有限公司 | 含钙通道阻滞剂和b族维生素的药物组合物及其用途 |
CN1969855B (zh) * | 2006-12-04 | 2010-09-01 | 北京华安佛医药研究中心有限公司 | 一种具有靶器官保护作用的药物组合物及其用途 |
CN101890165A (zh) * | 2009-05-22 | 2010-11-24 | 北京奥萨医药研究中心有限公司 | 降压组合物及用途 |
CN101897973A (zh) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | 含有钙拮抗剂和b族维生素的药物组合物作为制备治疗外周动脉疾病药物的应用 |
CN102579451A (zh) * | 2012-01-20 | 2012-07-18 | 孙飏 | 一种药物组合物及其用途和包装 |
CN103599537A (zh) * | 2013-11-15 | 2014-02-26 | 深圳奥萨医药有限公司 | 钙通道阻滞剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 |
CN107648256A (zh) * | 2017-11-13 | 2018-02-02 | 南京正亮医药科技有限公司 | 一种治疗高血压心衰的尼群地平药物组合物 |
CN109498643A (zh) * | 2018-12-06 | 2019-03-22 | 北京斯利安药业有限公司 | 一种叶酸组合物及其在制备改善老年失智药物中的应用 |
CN110339204A (zh) * | 2018-04-04 | 2019-10-18 | 北京斯利安药业有限公司 | 一种含有叶酸的组合物及其在制备脑卒中药物中的应用 |
CN110882249A (zh) * | 2019-11-08 | 2020-03-17 | 北京吾为尔创科技有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
CN111481554A (zh) * | 2019-01-29 | 2020-08-04 | 深圳奥萨医药有限公司 | 含氨氯地平和叶酸的片剂及其制备方法 |
-
2006
- 2006-01-12 CN CNB200610000693XA patent/CN100551442C/zh active Active
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1969855B (zh) * | 2006-12-04 | 2010-09-01 | 北京华安佛医药研究中心有限公司 | 一种具有靶器官保护作用的药物组合物及其用途 |
WO2009143662A1 (zh) * | 2008-05-30 | 2009-12-03 | 北京奥萨医药研究中心有限公司 | 含钙通道阻滞剂和b族维生素的药物组合物及其用途 |
CN101890165A (zh) * | 2009-05-22 | 2010-11-24 | 北京奥萨医药研究中心有限公司 | 降压组合物及用途 |
CN101897973A (zh) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | 含有钙拮抗剂和b族维生素的药物组合物作为制备治疗外周动脉疾病药物的应用 |
CN102579451A (zh) * | 2012-01-20 | 2012-07-18 | 孙飏 | 一种药物组合物及其用途和包装 |
CN103599537A (zh) * | 2013-11-15 | 2014-02-26 | 深圳奥萨医药有限公司 | 钙通道阻滞剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 |
CN107648256A (zh) * | 2017-11-13 | 2018-02-02 | 南京正亮医药科技有限公司 | 一种治疗高血压心衰的尼群地平药物组合物 |
CN110339204A (zh) * | 2018-04-04 | 2019-10-18 | 北京斯利安药业有限公司 | 一种含有叶酸的组合物及其在制备脑卒中药物中的应用 |
CN110339204B (zh) * | 2018-04-04 | 2023-09-01 | 北京斯利安药业有限公司 | 一种含有叶酸的组合物及其在制备脑卒中药物中的应用 |
CN109498643A (zh) * | 2018-12-06 | 2019-03-22 | 北京斯利安药业有限公司 | 一种叶酸组合物及其在制备改善老年失智药物中的应用 |
CN111481554A (zh) * | 2019-01-29 | 2020-08-04 | 深圳奥萨医药有限公司 | 含氨氯地平和叶酸的片剂及其制备方法 |
CN111481554B (zh) * | 2019-01-29 | 2022-11-25 | 深圳奥萨医药有限公司 | 含氨氯地平和叶酸的片剂及其制备方法 |
CN110882249A (zh) * | 2019-11-08 | 2020-03-17 | 北京吾为尔创科技有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
CN110882249B (zh) * | 2019-11-08 | 2021-04-30 | 北京吾为尔创科技有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
WO2021088672A1 (zh) * | 2019-11-08 | 2021-05-14 | 施慧达药业集团(吉林)有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100551442C (zh) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1824320A (zh) | 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 | |
CN1245155C (zh) | 口服药用脉冲释放剂型 | |
CN1222290C (zh) | 新组合物及其用途 | |
CN1720042A (zh) | DPP-IV抑制剂与PPAR-α化合物的组合 | |
CN1087517A (zh) | 用于降低高半胱氨酸水平的药物制剂 | |
CN1864675A (zh) | 柚皮素及其衍生物用于制备抗心脑系统疾病产品的用途 | |
CN1348369A (zh) | 改进释放胰岛素致敏剂和另一抗糖尿病药的药用组合物 | |
CN1215338A (zh) | 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物 | |
CN1765362A (zh) | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 | |
CN1062289A (zh) | 治疗心、血管肥大及增生的方法 | |
CN1635885A (zh) | 应用取代吲哚化合物增强一氧化氮合酶活性 | |
CN101068570A (zh) | 双嘧达莫治疗血小板抑制剂的抗药性的用途 | |
CN1625405A (zh) | 包含环加氧酶-2抑制剂和阿司匹林的组合 | |
CN1823805A (zh) | 一种地红霉素肠溶微丸及制备方法 | |
CN1269529C (zh) | 含有血管紧张素转化酶抑制剂和b族维生素的药物组合物 | |
CN1159313C (zh) | 地洛他定多元酸碱金属或碱土金属盐复合盐及其药用组合物 | |
CN1587269A (zh) | 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物 | |
CN1642557A (zh) | 醛固酮受体拮抗剂与烟酸或烟酸衍生物的组合 | |
CN101049293A (zh) | 乙酰半胱氨酸或其药用盐和细辛脑的药物组合物 | |
CN1813707A (zh) | 用于治疗高血压的含有单硝酸异山梨酯的药物组合物 | |
CN1642556A (zh) | 醛固酮受体拮抗剂与胆汁酸多价螯合剂的联合 | |
CN1813741A (zh) | 含有氨氯地平和特拉唑嗪的药物组合物 | |
CN1923228A (zh) | 三七提取物、丹参提取物和川芎嗪的药物组合物 | |
CN1903189A (zh) | 含有坦索罗辛和钙拮抗剂的药物组合物 | |
CN1870993A (zh) | 基于咪唑克生盐或其一种多晶型物的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN OSA MEDICINE CO., LTD. Free format text: FORMER OWNER: ANHUI BIOLOGICAL MEDICAL INST. Effective date: 20080822 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080822 Address after: Shenzhen high tech Zone of Nanshan District City, central high in a biological incubator 1301 post encoding: 518000 Applicant after: AUSA Pharmed Ltd. Address before: Box 153, Medical University Of Anhui, 81 Mei Shan Road, Anhui, Hefei: 230032 Applicant before: Anhui Biological Medical Science Inst. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Guangliang Inventor after: Wang Linlin Inventor after: Duan Yanyan Inventor after: Li Li Inventor after: Xu Xiping Inventor after: Xu Xin Inventor after: Wang Binyan Inventor before: Chen Guangliang Inventor before: Wang Linlin Inventor before: Duan Yanyan Inventor before: Li Li Inventor before: Xu Xiping |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN GUANGLIANG WANG LINLIN DUAN YANYAN LI LI XU XIPING TO: CHEN GUANGLIANG WANG LINLIN DUAN YANYAN LI LI XU XIPING XU XIN WANG BINYAN |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000313 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
CP02 | Change in the address of a patent holder |
Address after: Three, No. 16 biological incubator No. 518057, high tech Zone, central high tech Zone, Shenzhen, Guangdong, Nanshan District Patentee after: AUSA Pharmed Ltd. Address before: 518000 a biological incubator in central high tech Zone, Shenzhen, Nanshan District 1-301 Patentee before: AUSA Pharmed Ltd. |
|
CP02 | Change in the address of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190327 Address after: 518057 Phase III Biological Incubator No. 16, Zhongxin Zhongdao, Nanshan High-tech Zone, Shenzhen City, Guangdong Province Co-patentee after: Shenzhen Aosa Pharmaceutical Co., Ltd. Patentee after: AUSA Pharmed Ltd. Address before: 518057 Phase III Biological Incubator No. 16, Zhongxin Zhongdao, Nanshan High-tech Zone, Shenzhen City, Guangdong Province Patentee before: AUSA Pharmed Ltd. |
|
TR01 | Transfer of patent right |